Computer equipment accounts for almost 70% of e-waste material followed by telecommunication equipment (12%), electrical equipment (8%) and medical equipment (7%). Household e-waste accounts for the remaining 4% found the study.
The majority of e-waste generated is managed by the unorganized sector and scrap dealers who just dismantle the product instead of recycling it. It was found that only 1.5% of the country’s total e-waste gets recycled which causes a harm to natural resources.
According to the study, the main sources of electronic waste in India are the government and the public and private sectors, which account for almost 75% of the total waste generation. The contribution of individual households stands at 16%.
DS Rawat, secretary general of Assocham said “In India, about 4 lakh to 5 lakh child labourers in the age group of 10-15 years are engaged in various e-waste management activities in various yards and recycling workshops, but lack adequate protection and safeguards.”
-by Vrushali Mahajan, an intern at NewsGram. Twitter: Vrushali Mahajan
There should be some measures taken to stop this kind of waste generation. You cannot actually stop people from buying electronic products but we can surely take some steps to recycle the waste produced
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)
Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.
Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.
The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.
As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).
“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.
India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.
Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.
Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.
Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)
